Citation Information :
Saraogi R, Chandra S, Parulekar A, Pandia R, Shirsat A, Bhojwani H. Oral Natural Micronized Progesterone: A Review of Its Implications in Obstetric Indications. J South Asian Feder Obs Gynae 2024; 16 (5):611-616.
Progesterone is vital for sustaining pregnancy. Progesterone deficiency is considered a risk factor for infertility, threatened or recurrent miscarriages, and preterm births. Exogenous progesterone is a viable alternative for obstetric indications linked to low progesterone activity. Oral natural micronized progesterone (NMP) is beneficial in luteal phase support for in vitro fertilization (IVF), intrauterine insemination (IUI), threatened miscarriage, and preterm birth prevention. However, it necessitates frequent dosing and induces side effects owing to its active metabolites. To address these concerns, a sustained release (SR) formulation was developed and it presents a feasible option for addressing obstetric indications linked to inadequate endogenous progesterone levels. This review summarizes the benefits, efficacy, and safety of oral NMP and its SR formulation in obstetric indications.
Nagy B, Szekeres-Barthó J, Kovács GL, et al. Key to Life: Physiological role and clinical implications of progesterone. Int J Mol Sci 2021;22(20):11039. DOI: 10.3390/ijms222011039.
Di Renzo GC, Mattei A, Gojnic M, et al. Progesterone and pregnancy. Curr Opin Obstet Gynecol 2005;17(6):598–600. DOI: 10.1097/01.gco.0000191899.84567.4d.
Kuhl H. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric 2005;8 Suppl 1:3–63. DOI: 10.1080/13697130500148875.
Kolatorova L, Vitku J, Suchopar J, et al. Progesterone: A steroid with wide range of effects in physiology as well as human medicine. Int J Mol Sci 2022;23(14):7989. DOI: 10.3390/ijms23147989.
Sawankar SG, Malhotra J, Bora NM, et al. Pharmacological options to trigger final oocyte maturation in In Vitro fertilization. Journal of South Asian Federation of Obstetrics and Gynaecology. 2020;12(1):38–44.
Mujawar SA, Patil VW, Daver RG. Assessment of serum reproductive hormone concentrations in normal pregnancy. Journal of South Asian Federation of Obstetrics and Gynaecology. 2020;12(2):65–67.
Cable JK, Grider MH. Physiology, Progesterone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558960/. Accessed on: 6th December 2023.
Wagh GN, Kundavi Shankar KM, Bachani S. A review of conventional and sustained-release formulations of oral natural micronized progesterone in obstetric indications. Drugs Context 2021;10:2021-7-1. DOI: 10.7573/dic.2021-7-1.
Wagh G, Kundavi S, Bachani S. Conventional and sustained-release oral natural micronised progesterone in luteal phase support, threatened miscarriage, preterm birth, and high-risk pregnancy: A review. Authorea Preprints 2020 Oct 14. Available from: https://d197for5662m48.cloudfront.net/documents/publicationstatus/50061/preprint_pdf/a8398cebbd76dead5821dfb733e76b4a.pdf. Accessed on: 6th December 2023.
Di Renzo GC, Tosto V, Tsibizova V. Progesterone: History, facts, and artifacts. Best Pract Res Clin Obstet Gynaecol 2020;69:2–12. DOI: 10.1016/j.bpobgyn.2020.07.012.
Malik S, Krishnaprasad K. Natural micronized progesterone sustained release (SR) and luteal phase: Role redefined!! J Clin Diagn Res 2016;10(2):QE01–QE04. DOI: 10.7860/JCDR/2016/17278.7212.
Piette PCM. The pharmacodynamics and safety of progesterone. Best Pract Res Clin Obstet Gynaecol 2020;69:13–29. DOI: 10.1016/j.bpobgyn.2020.06.002.
García-Sáenz M, Ibarra-Salce R, Pozos-Varela FJ, et al. Understanding progestins: from basics to clinical applicability. J Clin Med 2023;12(10):3388. DOI: 10.3390/jcm12103388.
Fitzpatrick LA, Good A. Micronized progesterone: Clinical indications and comparison with current treatments. Fertil Steril 1999;72(3): 389–397. DOI: 10.1016/s0015-0282(99)00272-1.
Di Renzo GC, Giardina I, Clerici G, et al. The role of progesterone in maternal and fetal medicine. Gynecol Endocrinol 2012;28(11): 925–932. DOI: 10.3109/09513590.2012.730576.
Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 1991;56(6):1034–1039. DOI: 10.1016/s0015-0282(16)54713-x.
Wani R. Background. Am J Perinatol 2021;38:2–3. Available from: https://www.fogsi.org/wp-content/uploads/fogsi-focus/fogsi-focus-maternal-fetal-and-neonatal-medicine-2020.pdf. Accessed on: December 6, 2023.
de Lignières B. Oral micronized progesterone. Clin Ther 1999;21(1): 41–60; discussion 1–2. DOI: 10.1016/S0149-2918(00)88267-3.
Munshi R. Pharmacokinetic and pharmacodynamic features of progesterone: A special focus on the efficacy of different oral natural micronized sustained release progesterone formulations. Am J Perinatol 2021;38:8–11.
Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 1989;161(4):948–951. DOI: 10.1016/0002-9378(89)90759-x.
Palshetkar N. Evidence-based clinical recommendations in the management of threatened miscarriage. Am J Perinatol 2019;36:1–12.
Pouly JL, Bassil S, Frydman R, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996;11(10):2085–2089. DOI: 10.1093/oxfordjournals.humrep.a019054.
Friedler S, Raziel A, Schachter M, et al. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: A comparative study between vaginal and oral administration. Hum Reprod 1999;14(8):1944–1948. DOI: 10.1093/humrep/14.8.1944.
Tomic V, Tomic J, Klaic DZ. Oral micronized progesterone combined with vaginal progesterone gel for luteal support. Gynecol Endocrinol 2011;27(12):1010–1013. DOI: 10.3109/09513590.2011.569791.
Niu Y, Liu H, Li X, et al. Oral micronized progesterone versus vaginal progesterone for luteal phase support in fresh embryo transfer cycles: a multicenter, randomized, non-inferiority trial. Hum Reprod 2023;38(Supplement_2):ii24–ii33. DOI: 10.1093/humrep/deac266.
Licciardi FL, Kwiatkowski A, Noyes NL, et al. Oral versus intramuscular progesterone for in vitro fertilization: A prospective randomized study. Fertil Steril 1999;71(4):614–618. DOI: 10.5958/2319-5886.2014. 00028.9.
Malhotra J, Krishnaprasad K. Open-label, prospective, investigator initiated study to assess the clinical role of oral natural or synthetic progesterone during stimulated IUI cycles for unexplained infertility. J Clin Diagn Res 2016;10(1):QC08–QC10. DOI: 10.7860/JCDR/2016/17058.7106.
Gopinath PM, Desai RR. Open-label observational study to determine the success rate of first cycle Intra Uterine Insemination (IUI) involving luteal phase support with oral natural or synthetic progesterone. Int J Med Res Health Sci 2014;3(4):933–936. DOI: 10.5958/2319-5886.2014.00028.9.
Güven D, Batıoğlu A, Sari S, et al. The impact of progesterone supplementation on pregnancy rates after intrauterine insemination in patients developing a single follicle. Hum Fertil (Camb) 2016;19(2):111–113. DOI: 10.1080/14647273.2016.1186847.
Parveen R, Khakwani M, Tabassum S, et al. Oral versus vaginal micronized progesterone for the treatment of threatened miscarriage. Pak J Med Sci 2021;37(3):628–632. DOI: 10.12669/pjms.37.3.3700.
Turgal M, Aydin E, Ozyuncu O. Effect of micronized progesterone on fetal-placental volume in first-trimester threatened abortion. J Clin Ultrasound 2017;45(1):14–19. DOI: 10.1002/jcu.22384.
Siew JYS, Allen JC, Hui CYY, et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol 2018;228:319–324. DOI: 10.1016/j.ejogrb.2018.07.028.
Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst Rev 2019;2019(11):CD003511. DOI: 10.1002/14651858.CD003511.pub5.
Agarwal N. Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. CTRI/2016/09/007278 [Registered on: 16/09/2016]. Available from: https://ctri.nic.in/Clinicaltrials/pdf_generate.php.
Rai P, Rajaram S, Goel N, et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009;104(1):40–43. DOI: 10.1016/j.ijgo.2008.08.029.
Ashoush S, El-Kady O, Al-Hawwary G, et al. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: A randomized controlled trial. Acta Obstet Gynecol Scand 2017;96(12):1460–1466. DOI: 10.1111/aogs.13236.
Tariq MA, Naeem FA, Rasheed SE. Efficacy of oral progesterone in preterm births at a tertiary care hospital. J Med Physiol Biophys 2017;37:44–48.
Boelig RC, Della Corte L, Ashoush S, et al. Oral progesterone for the prevention of recurrent preterm birth: Systematic review and metaanalysis. Am J Obstet Gynecol MFM 2019;1(1):50–62. DOI: 10.1016/j.ajogmf.2019.03.001.
Noblot G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Rep Biol 1991;40(3):203–209. DOI: 10.5958/2319-5886.2014.00034.4.
Choudhary M, Suneja A, Vaid NB, et al. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet 2014;126(1):60–63. DOI: 10.1016/j.ijgo.2014.01.019.
Purandare AC, Hajare A, Krishnaprasad K, et al. Prescription event monitoring study to assess the safety profile of oral natural micronized progesterone sustained release in India. Int J Med Res Health Sci 2014;3(4):975–976. DOI: 10.5958/2319-5886.2014.00034.4.
Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151(6):746–750. DOI: 10.1016/0002-9378(85)90509-5.